Intensity Therapeutics, Inc. - Common Stock (INTS)
Healthcare › Biological Products, (No Diagnostic Substances)
Price History
Feb 9, 2026 — Mar 30, 2026Investment Snapshot
- P/B of 1.29 — trading near book value
- Piotroski F-Score 4/9 — moderate financial health
- Loss-making — negative ROE of -101.6%
Intensity Therapeutics, Inc. - Common Stock (INTS) is a Healthcare company operating in Biological Products, (No Diagnostic Substances), listed on the NASDAQ , with a market capitalisation of $15 million . Key value metrics: P/B ratio 1.29, Piotroski F-Score 4 out of 9 (moderate financial health) .
Value Score
Key Metrics
Current vs 5-Year Average
Based on 3 years of SEC filingsRevenue & Net Income
Financial Statements
| Metric | FY22 | FY23 | FY24 |
|---|---|---|---|
| Revenue | $X.XB | $X.XB | $X.XB |
| Gross Profit | $X.XB | $X.XB | $X.XB |
| Operating Income | $X.XB | $X.XB | $X.XB |
| Net Income | $X.XB | $X.XB | $X.XB |
| EBITDA | $X.XB | $X.XB | $X.XB |
| Total Assets | $X.XB | $X.XB | $X.XB |
| Total Liabilities | $X.XB | $X.XB | $X.XB |
Intensity Therapeutics, Inc. - Common Stock — Fundamental Analysis Summary
On financial health, INTS shows a moderate Piotroski F-Score of 4/9, and negative return on equity of -101.6% (sector average: -19.8%), and manageable leverage with a debt-to-equity ratio of 0.33.
StockPik's composite Value Score for INTS is 50/100 — an above-average value rating. The score is built from ten fundamental signals: P/E, P/B, PEG ratio, P/S ratio, return on equity, gross margin, debt-to-equity, current ratio, dividend yield, and Piotroski F-Score.
INTS shows earnings growing at 29%.